(March 19, 2021, 1:37 PM EDT) -- TACOMA, Wash. — A biotechnology company and two of its senior executives violated federal securities laws by misrepresenting to investors that its HIV-treatment drug could be used as a treatment for COVID-19, and then selling their shares of the stock at prices that were artificially inflated based on the misrepresentations, an investor argues in a March 17 securities class action complaint filed in Washington federal court....